Heron Therapeutics (HRTX) Assets (2010 - 2026)

Heron Therapeutics (HRTX) has reported Assets for 17 consecutive years, with $252.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets rose 8.69% year-over-year to $252.3 million; the trailing twelve-month figure through Jun 2026 stood at $252.3 million (up 8.69% YoY), and the FY2025 full-year result was $255.9 million, up 9.75% from the prior year.
• Assets rose to $252.3 million in Q2 2026 per HRTX's latest filing, from $246.2 million in the prior quarter.
• Across five years, Assets topped out at $273.7 million in Q1 2022 and bottomed at $201.2 million in Q2 2023.
• Historically, Assets has averaged $237.5 million across 5 years, with a median of $234.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets sank 39.65% in 2022, then advanced 12.76% in 2025.
• Over 5 years, Assets stood at $251.0 million in 2022, then decreased by 11.33% to $222.5 million in 2023, then gained by 4.78% to $233.1 million in 2024, then grew by 9.75% to $255.9 million in 2025, then decreased by 1.41% to $252.3 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $252.3 million, $246.2 million, and $255.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.